{"title":"Pembrolizumab联合Lenvatinib治疗血液透析患者的转移性肾细胞癌","authors":"Shimpei Yamashita, Hiroki Kawabata, Yuya Iwahashi, Satoshi Muraoka, Takahito Wakamiya, Fumiyoshi Kojima, Yasuo Kohjimoto, Shin-ichi Murata, Isao Hara","doi":"10.1002/iju5.70011","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>There is no clear evidence of the safety and efficacy of pembrolizumab plus lenvatinib combination therapy in patients on hemodialysis. This is the first report of a patient on hemodialysis to receive this combination therapy for metastatic renal cell carcinoma.</p>\n </section>\n \n <section>\n \n <h3> Case Presentation</h3>\n \n <p>A 60-year-old man on hemodialysis had cT3bN1M0 unclassified renal cell carcinoma. He received the combination therapy of pembrolizumab plus lenvatinib. Although the dose of lenvatinib was halved to 10 mg/day due to Grade 3 thrombocytopenia, 6 months later, the volumes of the primary lesion and lymph node metastasis were remarkably reduced.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Our case report suggests the feasibility of the combination therapy of pembrolizumab plus lenvatinib for patients with metastatic renal cell carcinoma who are undergoing hemodialysis.</p>\n </section>\n </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 3","pages":"223-226"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70011","citationCount":"0","resultStr":"{\"title\":\"Pembrolizumab Plus Lenvatinib for Metastatic Renal Cell Carcinoma in a Patient on Hemodialysis\",\"authors\":\"Shimpei Yamashita, Hiroki Kawabata, Yuya Iwahashi, Satoshi Muraoka, Takahito Wakamiya, Fumiyoshi Kojima, Yasuo Kohjimoto, Shin-ichi Murata, Isao Hara\",\"doi\":\"10.1002/iju5.70011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>There is no clear evidence of the safety and efficacy of pembrolizumab plus lenvatinib combination therapy in patients on hemodialysis. This is the first report of a patient on hemodialysis to receive this combination therapy for metastatic renal cell carcinoma.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Case Presentation</h3>\\n \\n <p>A 60-year-old man on hemodialysis had cT3bN1M0 unclassified renal cell carcinoma. He received the combination therapy of pembrolizumab plus lenvatinib. Although the dose of lenvatinib was halved to 10 mg/day due to Grade 3 thrombocytopenia, 6 months later, the volumes of the primary lesion and lymph node metastasis were remarkably reduced.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Our case report suggests the feasibility of the combination therapy of pembrolizumab plus lenvatinib for patients with metastatic renal cell carcinoma who are undergoing hemodialysis.</p>\\n </section>\\n </div>\",\"PeriodicalId\":52909,\"journal\":{\"name\":\"IJU Case Reports\",\"volume\":\"8 3\",\"pages\":\"223-226\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70011\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"IJU Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/iju5.70011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJU Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iju5.70011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Pembrolizumab Plus Lenvatinib for Metastatic Renal Cell Carcinoma in a Patient on Hemodialysis
Introduction
There is no clear evidence of the safety and efficacy of pembrolizumab plus lenvatinib combination therapy in patients on hemodialysis. This is the first report of a patient on hemodialysis to receive this combination therapy for metastatic renal cell carcinoma.
Case Presentation
A 60-year-old man on hemodialysis had cT3bN1M0 unclassified renal cell carcinoma. He received the combination therapy of pembrolizumab plus lenvatinib. Although the dose of lenvatinib was halved to 10 mg/day due to Grade 3 thrombocytopenia, 6 months later, the volumes of the primary lesion and lymph node metastasis were remarkably reduced.
Conclusion
Our case report suggests the feasibility of the combination therapy of pembrolizumab plus lenvatinib for patients with metastatic renal cell carcinoma who are undergoing hemodialysis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
